BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15344953)

  • 41. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Associations among Epstein-Barr virus subtypes, human leukocyte antigen class I alleles, and the development of posttransplantation lymphoproliferative disorder in bone marrow transplant recipients.
    Görzer I; Puchhammer-Stöckl E; van Esser JW; Niesters HG; Cornelissen JJ
    Clin Infect Dis; 2007 Mar; 44(5):693-5. PubMed ID: 17278061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
    Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
    J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of tolerance after haplocompatible T-depleted bone marrow transplantation.
    Merino A; Dror Y; Benkerrou M; Colombe BW; Cowan MJ
    Bone Marrow Transplant; 1993 Nov; 12(5):483-8. PubMed ID: 8298559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors.
    Ogawa H; Ikegame K; Kawakami M; Taniguchi Y; Oka Y; Kawase I
    Haematologica; 2004 Mar; 89(3):373-5. PubMed ID: 15020286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
    Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
    Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
    Faraci M; Caviglia I; Morreale G; Lanino E; Cuzzubbo D; Giardino S; Di Marco E; Cirillo C; Scuderi F; Dallorso S; Terranova P; Moroni C; Castagnola E
    Bone Marrow Transplant; 2010 Jun; 45(6):1052-5. PubMed ID: 19855442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
    Swinnen LJ
    Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
    Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
    Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
    Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia.
    Ohga S; Kanaya Y; Maki H; Takada H; Ohshima K; Kanda M; Nomura A; Suminoe A; Matsuzaki A; Hara T
    Bone Marrow Transplant; 2000 Jan; 25(2):209-12. PubMed ID: 10673683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.
    Liu Q; Xuan L; Liu H; Huang F; Zhou H; Fan Z; Zhao K; Wu M; Xu L; Zhai X; Zhang F; Liu C; Sun J; Huang X
    Am J Hematol; 2013 Jul; 88(7):550-5. PubMed ID: 23564232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes.
    Kernan NA; Flomenberg N; Dupont B; O'Reilly RJ
    Transplantation; 1987 Jun; 43(6):842-7. PubMed ID: 3296349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency.
    Shearer WT; Ritz J; Finegold MJ; Guerra IC; Rosenblatt HM; Lewis DE; Pollack MS; Taber LH; Sumaya CV; Grumet FC
    N Engl J Med; 1985 May; 312(18):1151-9. PubMed ID: 2984567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemical analysis and Epstein-Barr virus in the tonsils of transplant recipients and healthy controls.
    Mowry SE; Strocker AM; Chan J; Takehana C; Kalantar N; Bhuta S; Shapiro NL
    Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):936-9. PubMed ID: 18794437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients.
    Babel N; Schwarzmann F; Pruss A; Volk HD; Reinke P
    Transplant Proc; 2004 Nov; 36(9):2679-82. PubMed ID: 15621122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.